Your browser doesn't support javascript.
loading
Sinus arrhythmia caused by pemetrexed with carboplatin combination: A case report.
Quan, Xianghua; Zhang, Haonan; Xu, Wen; Cui, Mengna; Guo, Qie.
Afiliação
  • Quan X; Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, China.
  • Zhang H; Zibo City Zhangdian District People's Hospital, China.
  • Xu W; Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, China.
  • Cui M; Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, China.
  • Guo Q; Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, China.
Heliyon ; 8(10): e11006, 2022 Oct.
Article em En | MEDLINE | ID: mdl-36281405
Combination chemotherapy of pemetrexed and carboplatin is a standard treatment approach for non-small cell lung cancer (NSCLC). However, no prior reports have described cardiotoxicity associated with this therapeutic combination or sinus arrhythmia in oncological contexts. Here, we report the case of a 44-year-old female NSCLC patient that suffered from sinus arrhythmia following combined chemotherapeutic treatment with pemetrexed and carboplatin. The patient was successfully treated under medical guidance, and the condition was effectively reversed following the discontinuation of this chemotherapeutic regimen and medication prescribing. Overall, this represents a rare case of sinus arrhythmia in NSCLC patient during the first cycle of combined chemotherapy with pemetrexed and carboplatin. However, a putative etiological basis for this rare clinical entity remains to be established.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Heliyon Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Heliyon Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China